Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).

MLA

Smolen, Josef S., et al. “Patient-Reported Outcomes from a Randomised Phase III Study of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Biological Agents (RA-BEACON).” Annals of the Rheumatic Diseases, vol. 76, no. 4, Apr. 2017, pp. 694–700. EBSCOhost, https://doi.org/10.1136/annrheumdis-2016-209821.

APA

Smolen, J. S., Kremer, J. M., Gaich, C. L., DeLozier, A. M., Schlichting, D. E., Li Xie, Rooney, T., Bird, P., Sánchez Bursón, J. M., Genovese, M. C., & Combe, B. (2017). Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Annals of the Rheumatic Diseases, 76(4), 694–700. https://doi.org/10.1136/annrheumdis-2016-209821

Chicago

Smolen, Josef S., Joel M. Kremer, Carol L. Gaich, Amy M. DeLozier, Douglas E. Schlichting, Li Xie, Terence Rooney, et al. 2017. “Patient-Reported Outcomes from a Randomised Phase III Study of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Biological Agents (RA-BEACON).” Annals of the Rheumatic Diseases 76 (4): 694–700. doi:10.1136/annrheumdis-2016-209821.